Skip to main content
Premium Trial:

Request an Annual Quote

Silence Consolidates Operations Following Intradigm Acquisition

Premium

Silence Therapeutics said this week that it has begun a consolidation effort to streamline its operations following its acquisition of Intradigm (RNAi News 12/17/2009).

According to Silence, all research activities of the merged company will be conducted at its Berlin location. Silence, which is based in London, has maintained German operations since its 2005 acquisition of Atugen (RNAi News 7/29/2005).

Other functions including operations, business development, legal, and "certain drug-development activities, will be conducted in Palo Alto," Calif., where Intradigm was headquartered.

Silence said that as a result of the consolidation, it has laid off about 20 staffers, primarily in research and development, at both the Palo Alto and Berlin sites. The reorganization is expected to be completed in June.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.